We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protagonist Therapeutics Inc | NASDAQ:PTGX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 26.09 | 26.00 | 28.00 | 0 | 09:56:31 |
Title Of Each Class of
Securities To Be Registered |
| |
Amount
To Be Registered |
| |
Proposed
Maximum Offering Price Per Unit |
| |
Proposed
Maximum Aggregate Offering Price |
| |
Amount Of
Registration Fee |
| ||||||||||||
Common Stock, par value $0.00001 per share | | | | | 5,476,189(1) | | | | | $ | 21.00 | | | | | $ | 114,999,969 | | | | | $ | 12,547(2) | | |
| | |
Per share
|
| |
Total
|
| ||||||
Public offering price | | | | $ | 21.00 | | | | | $ | 99,999,984 | | |
Underwriting discounts and commissions(1) | | | | $ | 1.26 | | | | | $ | 5,999,999 | | |
Proceeds, before expenses, to Protagonist Therapeutics, Inc. | | | | $ | 19.74 | | | | | $ | 93,999,985 | | |
|
J.P. Morgan
|
| |
SVB Leerink
|
| |
Piper Sandler
|
| |
BMO Capital Markets
|
|
| | |
Page
|
| |||
| | | | S-2 | | | |
| | | | S-3 | | | |
| | | | S-9 | | | |
| | | | S-12 | | | |
| | | | S-13 | | | |
| | | | S-14 | | | |
| | | | S-16 | | | |
| | | | S-18 | | | |
| | | | S-22 | | | |
| | | | S-29 | | | |
| | | | S-29 | | | |
| | | | S-29 | | | |
| | | | S-29 | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 17 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 29 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | |
| | |
As of September 30, 2020
|
| |||||||||
| | |
Actual
|
| |
As
adjusted |
| ||||||
| | |
(in thousands, except share and per share data)
|
| |||||||||
Cash, cash equivalents and marketable securities
|
| | | $ | 199,999 | | | | | $ | 293,383 | | |
Stockholders’ equity:
|
| | | | | | | | | | | | |
Common stock, $0.00001 par value, 90,000,000 authorized; issued and outstanding, 37,314,873 actual and 42,076,777 as adjusted
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 434,603 | | | | | | 527,987 | | |
Accumulated other comprehensive loss
|
| | | | (88) | | | | | | (88) | | |
Accumulated deficit
|
| | | | (264,925) | | | | | | (264,925) | | |
Total stockholders’ equity
|
| | | | 169,590 | | | | | | 262,974 | | |
Total capitalization
|
| | | $ | 169,590 | | | | | $ | 262,974 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 21.00 | | |
|
Net tangible book value per share as of September 30, 2020
|
| | | $ | 4.54 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 1.71 | | | | | | | | |
|
As adjusted net tangible book value per share as of September 30,2020, after giving effect to
this offering |
| | | | | | | | | $ | 6.25 | | |
|
Dilution per share to new investors purchasing our common stock in this offering
|
| | | | | | | | | $ | 14.75 | | |
Name
|
| |
Number of shares
|
| |||
J.P. Morgan Securities LLC
|
| | | | 2,047,619 | | |
SVB Leerink LLC
|
| | | | 1,285,714 | | |
Piper Sandler & Co.
|
| | | | 1,000,000 | | |
BMO Capital Markets Corp
|
| | | | 428,571 | | |
Total
|
| | | | 4,761,904 | | |
| | |
Without option to
purchase additional shares exercise |
| |
With full option to
purchase additional shares exercise |
| ||||||
Per Share
|
| | | $ | 1.26 | | | | | $ | 1.26 | | |
Total
|
| | | $ | 5,999,999 | | | | | $ | 6,899,998 | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 17 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 29 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | | |
| | | | 31 | | |
|
J.P. Morgan
|
| |
SVB Leerink
|
| |
Piper Sandler
|
| |
BMO Capital Markets
|
|
1 Year Protagonist Therapeutics Chart |
1 Month Protagonist Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions